All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2022-09-15T14:19:16.000Z

Visual abstract | Eprenetapopt plus azacitidine as a post-allo-HCT treatment for patients with TP53-mutated AML and MDS: Results from a phase II trial

By Abhilasha Verma, Dylan Barrett
Sep 15, 2022
Share:
Learning objective: After reading this visual abstract, learners will be able to cite a new development in the treatment of AML/MDS.

Bookmark this article

The AML Hub is pleased to present a visual abstract representing key data from a phase II trial (NCT03931291) evaluating eprenetapopt plus azacitidine as a post-allogeneic hematopoietic stem cell transplantation treatment for patients with TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.



 

Visual Abstract

To download this visual abstract, click below.

Download here

More about...
AML-related mutationsEprenetapoptTP53Visual abstracts

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 80 days left ...

Related articles

Add bookmark

Visual abstract | Efficacy and safety of midostaurin plus intensive chemotherapy in newly diagnosed patients with FLT3-mutated AML

Here, we summarize the efficacy and safety findings from a phase IIIb trial of midostaurin plus idarubicin or...

Oct 25, 2023
Add bookmark

Visual abstract | Efficacy and safety of midostaurin plus intensive chemotherapy in newly diagnosed patients with FLT3-mutated AML

Here, we summarize the efficacy and safety findings from a phase IIIb...

Oct 25, 2023
Add bookmark

Visual abstract | Key updates to the classification of MDS in the 5th WHO Classification of Haematolymphoid Tumours

In this visual abstract, the MDS Hub summarizes the key updates to the classification of MDS from the 5th edition of the WHO...

Apr 10, 2023
Add bookmark

Visual abstract | Key updates to the classification of MDS in the 5th WHO Classification of Haematolymphoid Tumours

In this visual abstract, the MDS Hub summarizes the key updates to the...

Apr 10, 2023
Add bookmark

Visual abstract | Azacitidine, Lenalidomide and DLI as salvage therapy for MDS, CMML and sAML after allo-HSCT (AZALENA)

Visual abstract: Azacitidine, Lenalidomide and DLI as salvage therapy for MDS, CMML and sAML after allo-HSCT (AZALENA)

Jan 31, 2022
Add bookmark

Visual abstract | Azacitidine, Lenalidomide and DLI as salvage therapy for MDS, CMML and sAML after allo-HSCT (AZALENA)

Visual abstract: Azacitidine, Lenalidomide and DLI as salvage therapy for MDS,...

Jan 31, 2022
Add bookmark

Efficacy and safety of eprenetapopt (APR-246) combined with azacitidine in patients with TP53-mutant MDS and oligoblastic AML

Around 20% of patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) and 30–40% of patients with...

Jan 5, 2022
Add bookmark

Efficacy and safety of eprenetapopt (APR-246) combined with azacitidine in patients with TP53-mutant MDS and oligoblastic AML

Around 20% of patients with myelodysplastic syndromes (MDS) or acute...

Jan 5, 2022

Newsletter

Subscribe to get the best content related to AML delivered to your inbox